Summit Therapeutics (SMMT) Change in Cash (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Change in Cash came in at $312.9 million in Q2 2026, up 262.32% YoY from $86.3 million in Q2 2025, and up 363.45% on a QoQ basis from -$118.8 million in Q1 2026.
Summit Therapeutics (SMMT) Change in Cash (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Change in Cash data on file, last reported at $312.9 million in Q2 2026.
- Quarterly Change in Cash rose 262.32% year-over-year to $312.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $121.5 million (down 54.91% YoY) and the FY2025 annual result came in at $120.4 million, up 256.6% from the prior year.
- Change in Cash improved to $312.9 million in Q2 2026, from -$118.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $526.6 million in Q4 2022 to a low of -$577.6 million in Q1 2023.
- A 5-year average of $19.3 million and a median of -$2.1 million in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash jumped 6327.22% — and 2023, when it slumped 10307.42%.
- Tracing SMMT's Change in Cash over 5 years: stood at $526.6 million in 2022, then slumped by 90.96% to $47.6 million in 2023, then sank by 76.72% to $11.1 million in 2024, then tumbled by 219.88% to -$13.3 million in 2025, then surged by 2453.5% to $312.9 million in 2026.
- The last three Change in Cash figures came in at $312.9 million (Q2 2026), -$118.8 million (Q1 2026), and -$13.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 312.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 312.85 Mn |
| Mar 31, 2026 | -118.75 Mn |
| Dec 31, 2025 | -13.29 Mn |
| Sep 30, 2025 | -59.32 Mn |
| Jun 30, 2025 | 86.35 Mn |
| Mar 31, 2025 | 106.66 Mn |
| Dec 31, 2024 | 11.09 Mn |
| Sep 30, 2024 | 65.34 Mn |
| Jun 30, 2024 | -32.86 Mn |
| Mar 31, 2024 | -9.81 Mn |
| Dec 31, 2023 | 47.63 Mn |
| Sep 30, 2023 | -18.32 Mn |
| Jun 30, 2023 | -28.85 Mn |
| Mar 31, 2023 | -577.64 Mn |
| Dec 31, 2022 | 526.64 Mn |
| Sep 30, 2022 | 64.64 Mn |
| Jun 30, 2022 | -20.12 Mn |
| Mar 31, 2022 | 5.66 Mn |
| Dec 31, 2021 | -8.46 Mn |
| Sep 30, 2021 | -23.14 Mn |